Currently Viewing:
ACO & Emerging Healthcare Delivery Coalition®
Dr Justin Bachmann Discusses Cardiac Rehabilitation in Patients
February 08, 2018
Dr Justin Bachmann on How Cardiology Is Handling Transition to Value-Based Care
January 22, 2018
Dr Justin Bachmann Discusses Consequences of Value-Based Care Being Done Incorrectly
January 06, 2018
Dr Shantanu Agrawal: How Quality Measures Help to Address Health Inequities
December 31, 2017
Dr Shantanu Agrawal on the Challenge of Adjusting Measures for Social Risk Factors
December 14, 2017
Dr Mark Friedberg Discusses His Findings on Workplace Conditions in FQHCs
December 05, 2017
Barbara Balik: Why Clinician Burnout Needs to Be Addressed
November 29, 2017
Currently Reading
Clay Alspach Explains How Changes in the FDA Will Affect Biosimilars
November 27, 2017
Barbara Balik Explains the Biggest Stressors That Cause Clinician Burnout
November 19, 2017
Dr Justin Bachmann: Challenges of Implementing Behavioral Interventions in Cardiac Care
November 18, 2017
Dr Frank James Discusses Responses to the Opioid Epidemic
November 11, 2017
Moving Specialties and the Whole Healthcare Industry to Value-Based Payment Models
November 01, 2017
Dr Frank James on Improving Treatment for Addiction
November 01, 2017
The Challenge of Adjusting Health Measures for Social Risk Factors
October 30, 2017
Navigating the Politics of the Healthcare Landscape
October 30, 2017
Making the Case for Integrated Care and Physician Engagement With Addiction Patients
October 30, 2017
Dr Shantanu Agrawal: Incorporating Social Risk Factors Into Performance Measures
October 28, 2017
5 Important Healthcare Issues Discussed at the ACO Coalition Meeting
October 28, 2017

Clay Alspach Explains How Changes in the FDA Will Affect Biosimilars

Clay Alspach, JD, principal, Leavitt Partners, explains how biosimilars will be affected by changes in the FDA under Scott Gottlieb's leadership.
 


Clay Alspach, JD, principal, Leavitt Partners, explains how biosimilars will be affected by changes in the FDA under Scott Gottlieb's leadership.

Transcript (slighly modified)

What changes in the FDA under Scott Gottlieb’s leadership do you think will have the best chance of meaningfully impacting drug prices?

It’s clear that drug pricing is a priority for President Trump, and Commissioner Gottlieb at FDA has already taken steps to prioritize generic applications. He’s also put out information on biosimilars to help educate physicians, as well as provide additional guidance for those producing them. So, I think that will be the area where they try to make the most difference.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!